Table 5.
Analysis | Characterization | Description | Class 1 | Class 2 | P-val e |
---|---|---|---|---|---|
Dura |
Biologicalb |
Dorso-ventral axis formation |
3/3 Up |
3/3 Down |
0.001 |
|
|
Pathways in cancer |
4/6 Up |
4/6 Down |
0.031 |
|
Radiologicalc |
Area3 |
Larger |
Smaller |
0.006 |
|
|
Supraoccipital bone |
Larger |
Smaller |
0.006 |
|
|
Opisthion to reference |
Larger |
Smaller |
0.046 |
|
Clinical |
NA |
NA |
NA |
NA |
Blood |
Biologicalb |
Ribosome |
10/10 Up |
10/10 Down |
2.80E-09 |
|
|
Spliceosome |
5/6 Up |
5/6 Down |
0.005 |
|
|
Proteosome |
3/3 Up |
3/3 Down |
0.007 |
|
|
RNA degradation |
2/3 Up |
2/3 Down |
0.014 |
|
|
Oxidative phosphorylation |
2/4 Up |
2/4 Down |
0.018 |
|
Radiologicalc |
Boogaard’s angle |
Smaller |
Larger |
0.004 |
|
|
Basion to reference |
Larger |
Smaller |
0.016 |
|
|
Tentorium |
Smaller |
Larger |
0.036 |
Clinicald | Paternal age | Younger | Older | 0.021 |
aOnly nominally significant results are shown. In addition, only the two most significant clustering analyses were included in the table.
bThe top 100 ranked genes from each analysis were used as input into DAVID v6.7 for the pathway analysis. KEGG pathways with a Fisher exact p < 0.05 are listed. Additional filtering was applied using DAVID's default settings: minimum of 2 genes present in the pathway and an EASE score < 0.1. For each class, the total number of genes present in each pathway and whether they are down- or up-regulated with respect to the other class are noted.
cLogistic regression was carried out including age at MRI, sex, and race as covariates in the model.
dA t-test assuming equal variance was performed.
eThese are not adjusted for multiple testing.